Prothena (PRTA) Competitors

Prothena has a net margin of -80.68% compared to Recursion Pharmaceuticals' net margin of -945.94%. Prothena's return on equity of -16.33% beat Recursion Pharmaceuticals' return on equity.

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 10.4% of Prothena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Recursion Pharmaceuticals has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Prothena has a beta of -0.3, suggesting that its stock price is 130% less volatile than the broader market.

Recursion Pharmaceuticals currently has a consensus price target of $8.10, suggesting a potential upside of 151.55%. Prothena has a consensus price target of $23.75, suggesting a potential upside of 171.12%. Given Prothena's stronger consensus rating and higher probable upside, analysts plainly believe Prothena is more favorable than Recursion Pharmaceuticals.

Prothena has lower revenue, but higher earnings than Recursion Pharmaceuticals. Prothena is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

In the previous week, Recursion Pharmaceuticals had 16 more articles in the media than Prothena. MarketBeat recorded 24 mentions for Recursion Pharmaceuticals and 8 mentions for Prothena. Prothena's average media sentiment score of 0.35 beat Recursion Pharmaceuticals' score of 0.28 indicating that Prothena is being referred to more favorably in the news media.

Prothena has a beta of -0.3, indicating that its share price is 130% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, indicating that its share price is 175% less volatile than the broader market.

Bicara Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.33% beat Bicara Therapeutics' return on equity.

Bicara Therapeutics has lower revenue, but higher earnings than Prothena. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Prothena presently has a consensus price target of $23.75, indicating a potential upside of 171.12%. Bicara Therapeutics has a consensus price target of $30.27, indicating a potential upside of 7.89%. Given Prothena's stronger consensus rating and higher probable upside, research analysts plainly believe Prothena is more favorable than Bicara Therapeutics.

In the previous week, Prothena had 4 more articles in the media than Bicara Therapeutics. MarketBeat recorded 8 mentions for Prothena and 4 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.61 beat Prothena's score of 0.35 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

97.1% of Prothena shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

97.1% of Prothena shares are owned by institutional investors. 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 10.4% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Prothena has a net margin of -80.68% compared to Syndax Pharmaceuticals' net margin of -87.52%. Prothena's return on equity of -16.33% beat Syndax Pharmaceuticals' return on equity.

Prothena has lower revenue, but higher earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Syndax Pharmaceuticals has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Prothena has a beta of -0.3, indicating that its stock price is 130% less volatile than the broader market.

In the previous week, Syndax Pharmaceuticals had 18 more articles in the media than Prothena. MarketBeat recorded 26 mentions for Syndax Pharmaceuticals and 8 mentions for Prothena. Prothena's average media sentiment score of 0.35 beat Syndax Pharmaceuticals' score of -0.45 indicating that Prothena is being referred to more favorably in the news media.

Syndax Pharmaceuticals presently has a consensus price target of $42.36, indicating a potential upside of 107.66%. Prothena has a consensus price target of $23.75, indicating a potential upside of 171.12%. Given Prothena's higher probable upside, analysts plainly believe Prothena is more favorable than Syndax Pharmaceuticals.

Prothena has a beta of -0.3, meaning that its stock price is 130% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Taysha Gene Therapies has a net margin of 0.00% compared to Prothena's net margin of -80.68%. Prothena's return on equity of -16.33% beat Taysha Gene Therapies' return on equity.

Taysha Gene Therapies has higher revenue and earnings than Prothena. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

In the previous week, Prothena had 3 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 8 mentions for Prothena and 5 mentions for Taysha Gene Therapies. Prothena's average media sentiment score of 0.35 beat Taysha Gene Therapies' score of 0.33 indicating that Prothena is being referred to more favorably in the media.

Prothena currently has a consensus price target of $23.75, suggesting a potential upside of 171.12%. Taysha Gene Therapies has a consensus price target of $12.77, suggesting a potential upside of 94.65%. Given Prothena's higher possible upside, analysts plainly believe Prothena is more favorable than Taysha Gene Therapies.

97.1% of Prothena shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 10.4% of Prothena shares are held by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.